Holen Sie sich die Stockscreener-App
0.5215
3.70%
0.0186
Handel nachbörslich:
.52
-0.0015
-0.29%
Schlusskurs vom Vortag:
$0.5029
Offen:
$0.5061
24-Stunden-Volumen:
5.35M
Relative Volume:
0.78
Marktkapitalisierung:
$144.87M
Einnahmen:
$2.02M
Nettoeinkommen (Verlust:
$-97.59M
KGV:
-0.9074
EPS:
-0.5747
Netto-Cashflow:
$-102.38M
1W Leistung:
-6.42%
1M Leistung:
-12.59%
6M Leistung:
-18.82%
1J Leistung:
-70.87%
1-Tages-Spanne:
$0.5032
$0.5343
1-Wochen-Bereich:
$0.5007
$0.5689
52-Wochen-Spanne:
$0.5007
$2.55
Humacyte Inc Stock (HUMA) Company Profile
Firmenname
Humacyte Inc
Sektor
Branche
Telefon
919-313-9633
Adresse
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.5215 | 154.82M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-27 | Eingeleitet | Barclays | Overweight |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2023-12-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-14 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-16 | Herabstufung | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | Eingeleitet | Cowen | Outperform |
| 2021-09-24 | Eingeleitet | Oppenheimer | Outperform |
| 2021-09-22 | Eingeleitet | BTIG Research | Buy |
| 2021-09-16 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Humacyte Inc Aktie (HUMA) Neueste Nachrichten
Form 8K Humacyte Inc For: 28 September By Investing.com - Investing.com Nigeria
Humacyte Director D. Scott Coward Files Form 3 Reporting No Beneficial Ownership - kalkinemedia.com
Two new directors join Humacyte (HUMA), one on the audit committee and one on the commercial committee. - Stock Titan
Humacyte, Inc.Common Stock (NQ: HUMA - The Chronicle-Journal
Humacyte, Inc. Announces Board and Committees Appointments - marketscreener.com
Humacyte Adds Scott Coward and Paul Kuznik to Board Ahead of Dialysis Launch - citybiz
A new board member brings more than 30 years in vascular care to Humacyte - Stock Titan
Humacyte Inc (HUMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Humacyte, Inc. (HUMA) Stock Analysis: Unpacking a 221.68% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Humacyte (HUMA) Extends Rally with +0.88% Gain 2026-09-17Gap and Go - careplusvn.com
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte (NASDAQ: HUMA) director now holds 50,000 shares - Stock Titan
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Humacyte CEO to speak in New York on Sept. 16 - Stock Titan
Humacyte ATEV shows superiority in Phase 3 V012 study - scanx.trade
Hospitals can keep an emergency blood-vessel graft for 36 months, up from 18 - Stock Titan
Humacyte Gets US FDA Clearance to Extend Symvess Shelf Life to 36 Months - Yahoo Finance
HC Wainwright raises Humacyte price target to $4 - scanx.trade
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc. Warrant (HUMAW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Humacyte Inc. Warrant (HUMAW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Humacyte Inc. Warrant (HUMAW) Peer Comparison – Compare with Others - Value Research
Humacyte (NASDAQ: HUMA) pulls redeemable warrants from Nasdaq - Stock Titan
Humacyte plans November FDA filing for dialysis access use By Investing.com - Investing.com Nigeria
Humacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 Data - Quiver Quantitative
Price to sales forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds. - Pluang
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Moomoo
Humacyte (HUMA) Shares: Records a 7.28% Decrease to $0.68 on the Day; Next Session - vinanet.vn
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.25 - Moomoo
Humacyte (HUMA) Q2 2026 Earnings Call Transcript - AOL.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Australia
Humacyte publishes Phase 3 trial results in Lancet journal - Investing.com
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - The Manila Times
Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results - TradingView
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti - Ad-hoc-news.de
MSN Money - MSN
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
Humacyte Announces First Symvess Implants in Arizona by Phoenix Vascular Surgeon Jeromy Brink - Quiver Quantitative
A bioengineered blood vessel is ready off the shelf for urgent surgery - Stock Titan
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Finanzdaten der Humacyte Inc-Aktie (HUMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Humacyte Inc-Aktie (HUMA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jones Keith Anthony | Director |
Aug 20 '26 |
Buy |
0.69 |
10,000 |
6,930 |
40,000 |
| Jones Keith Anthony | Director |
Aug 17 '26 |
Buy |
0.59 |
30,000 |
17,820 |
30,000 |
| Sebelius Kathleen | Director |
May 19 '26 |
Buy |
0.88 |
56,818 |
50,000 |
148,025 |
| Constantino Michael T. | Director |
May 18 '26 |
Buy |
0.89 |
11,000 |
9,840 |
43,950 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
267,213 |
| Parikh Shamik J | Chief Medical Officer |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
272,713 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):